Ionis Pharmaceuticals
Ionis Pharmaceuticals Inc is an American biotechnology company pioneering antisense technology for ribonucleic acid targeted drug discovery. The company discovers, develops, and commercializes RNA-targeted therapeutics designed to treat severe cardiovascular, neurological, and rare genetic diseases. Its proprietary platform enables the generation of antisense oligonucleotides that selectively regulate disease-causing protein synthesis. Revenue is derived from commercial sales of therapies like Spinraza and Wainua, milestone payments, and research royalties under partnerships with major pharmaceutical firms. Ionis holds a commanding position in genetic and RNA-targeted drug innovation globally, maintaining a deep pipeline of clinical-stage candidates. The company is headquartered in Carlsbad, California, United States, and its common stock is traded on the Nasdaq Global Select Market.
13 of the funds FundTelligence covers report a position in Ionis Pharmaceuticals.
- Legal name
- Ionis Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 13
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding Ionis Pharmaceuticals
- DNB Bioteknologi — DNB · 2.55 % (full portfolio disclosed, September 2026)
- BNP Health Care Innovators — BNP Paribas · 1.48 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.79 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 0.5 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.42 % (full portfolio disclosed, October 2026)
- JPM Global Healthcare Fund — JPM · 0.3 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Convertible Bond — Schroders · 0.29 % (full portfolio disclosed, June 2026)
- Handelsbanken Amerika SMB Tema — Handelsbanken · 0.22 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 13 funds holding it.